Welcome to our dedicated page for Turn Therapeutics news (Ticker: TTRX), a resource for investors and traders seeking the latest updates and insights on Turn Therapeutics stock.
Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.
News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.
Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.
Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.
Turn Therapeutics (Nasdaq: TTRX) appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs on February 17, 2026.
Dr. Redfield, former CDC director, will advise on clinical development, public health implications, and regulatory strategy for the company’s lead investigational therapy GX-03, currently in Phase 2 trials.
Turn Therapeutics (Nasdaq: TTRX) announced CEO Brad Burnam will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference (virtual) on Feb 25, 2026, 8:00–8:30 a.m. ET and at the 46th Annual TD Cowen Healthcare Conference in Boston on Mar 2, 2026, 1:10–1:40 p.m. ET.
Management will update the dermatology pipeline, including the ongoing Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis, and will hold one-on-one investor meetings. Webcasts and replays will be available on the company’s Investors website for approximately 30 days.
Turn Therapeutics (Nasdaq: TTRX) provided corporate, pipeline, and financial updates ahead of the 2026 J.P. Morgan Healthcare Conference. Key items include a Phase 2 randomized trial of GX-03 for moderate‑severe atopic dermatitis on track with both interim and topline data expected in H1 2026, the appointment of Martin Dewhurst to the board, and an expanded intranasal vaccine program adding an influenza candidate with in‑vitro and in‑vivo studies planned in Q1 2026. A strategic partnership with Medline is expected to generate near‑term revenue in 2026. The company used a share purchase agreement to bolster cash, extending operational runway into late 2026.
Turn Therapeutics (NASDAQ: TTRX) announced the appointment of Martin Dewhurst to its Board of Directors on January 7, 2026. Dewhurst brings over 30 years of global life sciences leadership with a focus on mergers and acquisitions, including long tenure at McKinsey & Company and co-founding the McKinsey Health Institute. The company said his expertise will support a disciplined, M&A-focused strategy to expand the pipeline, guide capital allocation, and pursue value-enhancing partnerships and acquisitions.
Dewhurst currently advises PJT Partners, partners with Lightrock, and holds board roles such as at Distalmotion.
Turn Therapeutics (Nasdaq: TTRX) reported third-quarter 2025 results and corporate updates on November 13, 2025. Key developments include beginning Nasdaq trading on October 8, 2025, a global supply, development, and license agreement with Medline, two new board appointments, and a new VP of corporate communications.
Operational updates: commenced a clinical trial of a topical IL-36/IL-31 inhibitor for eczema and reported intranasal vaccine stability of 14 days at ambient temperature and 28 days under refrigeration. Financials: Q3 net loss $1.904M, R&D $158,699, G&A $1.754M, and cash $3.106M as of September 30, 2025.
Turn Therapeutics (Nasdaq: TTRX) announced that CEO Bradley Burnam spoke with Dr. Robert Redfield, former CDC director, on Nov 11, 2025 about healthcare communications and restoring public trust in science.
The interview, titled "Redfield’s Warning: Former CDC Director on COVID’s Biggest Casualty-Trust in Science", is available on major podcast platforms, YouTube, and the Turn Therapeutics investor relations website. The conversation emphasizes fact-based science, data-driven public health messaging, and continued dialogue between biotech leaders and public officials.
Dr. Redfield is described as a virologist who led CDC from 2018–2021 and contributed to early HIV research including the Walter Reed staging system and evidence of active HIV replication across disease stages.
Turn Therapeutics (Nasdaq: TTRX) said its topical IL-36/IL-31 inhibitor GX-03 was named one of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online on Nov 11, 2025. The company said GX-03 is the first topical agent targeting IL-36 and demonstrated inhibition of IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn described GX-03 as a potential alternative to systemic and injectable therapies for eczema and psoriasis. The company also said it expects to announce topline data from its lead severe eczema program in early 2026.
Patient Care Online is described as a clinical news resource for office-based clinicians covering drug approvals, research commentary, and clinical trial highlights.
Turn Therapeutics (Nasdaq: TTRX) announced on November 4, 2025 the appointment of Andrew Scott as Vice President of Corporate Communications.
Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, and will support the company’s licensing and partnership initiatives as Turn advances toward the completion of its Phase 2 clinical program. He joins after a 30-year capital markets career, including a Managing Director role at ThinkEquity and prior business development work at Fortress Biosciences, and has helped raise approximately $3 billion across life-sciences transactions.
Turn Therapeutics (Nasdaq: TTRX) on October 30, 2025 announced a global supply, development, and license agreement with Medline to combine Turn's PermaFusion® delivery platform with Medline's scale and distribution.
The collaboration establishes a long-term partnership to develop, manufacture, and commercialize professional and consumer products; financial terms, specific product categories, and timelines are confidential. The company said it will provide updates as joint initiatives progress toward commercialization and as development milestones are achieved.
Turn Therapeutics (Nasdaq: TTRX) provided a shareholder update on October 22, 2025 outlining clinical progress and a flexible capital plan following a dilution-sparing direct listing.
Key items: a $85 million GEM Global Yield agreement provides on-demand financing; the randomized Phase 2 trial of topical GX-03 for moderate to severe eczema is ~25% complete with >1,000 confirmed study product applications and a blinded aggregate safety summary reporting no safety or tolerability concerns to date; topline GX-03 results are anticipated in 2026. Turn also plans in‑vivo studies for a thermostable intranasal vaccine initiative in Q4 2025. The company hosted a shareholder webinar on October 22, 2025 at 2:00 PM ET.